Fig. 2: Hemagglutination inhibition, microneutralization, and surface plasmon resonance by vaccine strain and group. | Nature Communications

Fig. 2: Hemagglutination inhibition, microneutralization, and surface plasmon resonance by vaccine strain and group.

From: An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial

Fig. 2

Antibody responses to influenza A/H5N1 A/Indonesia/05/2005 (clade 2.1) and A/Vietnam/1203/2004 (clade 1) at baseline, Day 57 (28 days post-second intranasal vaccination), Day 197 (immediately before intramuscular H5N1 IIV boost), and Day 225 (28 days post intramuscular H5N1 IIV boost). Serum HAI (A) and microneutralization (B) titers are shown as individual results for each participant (n = 8 per group, except as per the consort diagram in Fig. 1), with lines connecting the geometric mean titers at each timepoint with 95% confidence intervals. C Individual Surface Plasmon Resonance (SPR) responses with connecting mean and standard deviations. HAI assays were also conducted with specimens from Day 204 (seven days post intramuscular H5N1 IIV boost, with samples available from n = 8 participants in group A and C, n = 7 in group B, and n = 6 in groups D, E). For the HAI assay, sera that were negative at the initial dilution were assigned a titer of 5. For the MN assay, sera that were negative at the initial dilution were assigned a titer of 10. Dotted lines in (A and B) show the 1:40 dilution. Low-dose (Group A), medium-dose (Group B), and high-dose (Group C) of rH5-NE are shown in maroon, orange, and yellow. Controls, including the unadjuvanted rH5 (Group D) and placebo (Group E), are shown in cyan and gray.

Back to article page